INS and type 2 diabetes mellitus: In a phase 3 study enrolling 1,444 subjects evaluated at 52 wk, the effects on glycemia and body weight of once-weekly tirzepatide (5, 10, and 15 mg) versus once-daily titrated insulin degludec in patients with type 2 diabetes in inadequate glycemic control with a stable dose of metformin with or without SGLT2 inhibitors.